Sustained platelet-sparing thromboprotective effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

Authors: Rohini Sharma\textsuperscript{1*}, Janet Graham\textsuperscript{2*}, Sarah Blagden\textsuperscript{3}, Hani Gabra\textsuperscript{3}.

Institutions:
\texttt{r.sharma@imperial.ac.uk}, Department of Experimental Medicine, Imperial College, London\textsuperscript{1}
\texttt{Janet.graham@ggc.scot.nhs.uk}, Department of Oncology, University of Glasgow, Glasgow\textsuperscript{2},
\texttt{s.blagden@imperial.ac.uk}, Ovarian Cancer Action (HHMT) Research Centre, Imperial College, London\textsuperscript{3}
\texttt{h.gabra@imperial.ac.uk}, Ovarian Cancer Action (HHMT) Research Centre, Imperial College, London\textsuperscript{3}

*Joint first authorship

Address for correspondence:
Rohini Sharma, Hani Gabra, Department of Experimental Medicine, Imperial College, Ovarian Cancer Action (HHMT) Research Centre, Imperial College, London Hammersmith Campus, Du Cane Road, London W12 ONN, UK
E-mail: \texttt{r.sharma@imperial.ac.uk}
\texttt{h.gabra@imperial.ac.uk}

Keywords: ovarian cancer, resistance, chemotherapy, dose-dense, carboplatin, paclitaxel, thrombocytopenia
Abstract

**Background:** Platinum agents have shown demonstrable activity in the treatment of patients with platinum resistant, recurrent ovarian cancer when delivered in a “dose-dense” fashion. However, the development of thrombocytopenia limits the weekly administration of carboplatin to no greater than AUC 2. Paclitaxel has a well-described platelet sparing effect however its use to explicitly provide thromboprotection in the context of dose dense carboplatin has not been explored.

**Methods:** We treated seven patients with platinum resistant ovarian cancer who had previously received paclitaxel or who had developed significant peripheral neuropathy precluding the use of further full dose weekly paclitaxel.

**Results:** We were able to deliver up to 18 weekly cycles of carboplatin AUC 3 and paclitaxel 20mg/m² with no thrombocytopenia or worsening of neuropathic side-effects, and with good activity.

**Conclusions:** We conclude that this regimen may be feasible and active, and could be formally developed as a “platinum-focussed dose-dense scaffold” into which targeted therapies that reverse platinum resistance can be incorporated, and merits further evaluation for patients that relapse and require treatment after weekly paclitaxel therapy.
Introduction

Ovarian cancer is the leading cause of death from gynaecologic malignancies in the United Kingdom, and is the fourth most common cause of cancer mortality in women [1]. Despite 70-80% overall response to initial therapy, the majority of patients with epithelial ovarian cancer will experience disease relapse and will require further chemotherapy [2, 3]. Several therapeutic options are available and the decision as to which therapy to commence is dependent on the time from last platinum chemotherapy to decision to treat, known as the platinum-free interval (PFI) [4, 5]. The PFI is a predictor of response not only to second-line treatment with platinum-based chemotherapy but also other active agents including the taxanes, topoisomerase I inhibitors and anthracyclines [6]. Stemming from the original paper by Markmann and colleagues in 1991, patients who relapse within 6 months are termed platinum resistant, those who never respond platinum refractory and those who relapse after more than one year platinum sensitive [4]. The term partially sensitive has come into use more recently to describe the patients with a PFI of 6 to 12 months. The probability of response to platinum rechallenge increases with the PFI, from >60% in patients relapsing >12 months since last platinum therapy to below 10% in patients relapsing within 6 months [4]. There is increasing evidence, however, that by administering platinum in a 'dose-dense' manner, resistance can be overcome resulting in significant improvements in response [7].

Dose intensity is defined as the amount of drug administered per unit of time, and can be increased in a number of ways [8]. Firstly, the dose delivered per cycle can be increased (dose intensity), secondly, the dosing interval can be reduced keeping the dose per cycle and overall dose the same (dose densification), and finally both the dosing interval can be reduced and the overall dose increased (increased dose intensity, total dose, and dose density) [9]. The concept of dose manipulation, in particular the delivery of dose dense chemotherapy is not novel and has been extensively studied in a number of tumour types in particular particularly breast cancer where significant improvements in both disease free survival and overall survival have been reported with dose dense therapy with an acceptable side effect profile [10]. More recently, use of adjuvant dose dense weekly paclitaxel in combination with conventional platinum has demonstrated significant improvement in progression free survival and overall survival in ovarian cancer [11].

The dose dense approach in ovarian cancer was first pioneered by van der Burg who investigated the utility of weekly cisplatin (70mg/m²/week) and daily oral etoposide induction chemotherapy over 7 weeks followed by oral etoposide maintenance in patients with resistant and refractory disease [7]. Using this regimen response rates of 46% were reported in patients with resistant and refractory disease. However, the induction phase of this regimen could not be prolonged due to significant myelosuppression and nephrotoxicity. A number of different 'dose-dense' carboplatin and paclitaxel regimens have since been developed for the treatment of both front line and recurrent ovarian cancer, both by our group and others, and have established the feasibility and tolerability of delivering combination platinum and paclitaxel [7, 12]. Common to all these studies is the development of neurotoxicity associated with weekly dosing of paclitaxel [11]. The reported incidence of grade 3/4 neurotoxicity ranges from 2 – 94%. The development of neuropathy may have a
negative which may impact on the administered dose intensity and negatively influence patients’ quality of life, an important consideration in this essentially palliative population. Furthermore, platinum resistant patients with existing peripheral neuropathy or other co-morbidities such as diabetes mellitus are poor candidates for dose dense approaches that utilise either cisplatin or paclitaxel because of the risk of further deterioration of their neurological symptoms.

In the context of dose dense therapy the role of taxanes is twofold, firstly to impart a cytotoxic effect and secondly to improve the feasibility of carboplatin delivery by utilising the thromboprotective platelet sparing effect of paclitaxel [13, 14][12, 13]. Clinically, it is accepted that carboplatin given at AUC>2 weekly is non-feasible due to development of dose-limiting thrombocytopenia, whereas the addition of weekly paclitaxel, 70-90 mg/m², allows higher doses of carboplatin to be delivered weekly [15-17][14]. However this dose dense schedule sits close to the limits of feasibility, and may reduce the ability to subsequently integrate targeted therapies, directed at reversing platinum resistance into the weekly therapy regimen, a major forward aim of improving responses in the context of platinum resistant disease. It is not unreasonable to consider that maximising platinum dose intensity may enhance response in platinum resistant patients, and that integrating molecular targeted therapies that reverse platinum resistance may enhance that response. We therefore chose to in such a scenario, delivering a lower but sufficient dose of paclitaxel to prevent thrombocytopenia when delivering dose dense platinum. in order to may minimise neuropathy in those patients with co-morbidities such as diabetes or pre-existing (or developing) taxane neuropathy.

In this paper, we hypothesised that the platelet sparing thromboprotective effect of paclitaxel occurs at doses lower than that required for response. Therefore, patients receiving weekly dose dense therapy who developed neuropathy necessitating the reduction of paclitaxel dose were afforded the opportunity to continue chemotherapy at reduced paclitaxel dose whilst maintaining platinum dose density. We describe here a case series of patients receiving dose dense weekly carboplatin AUC 3 with paclitaxel 20 mg/m² day 1, 8, 15 q4 weekly where reductions in paclitaxel dose were required due to clinical indication. We demonstrate that the addition of low dose paclitaxel allows delivery of weekly dose dense carboplatin AUC 3 by maintaining platelet counts the thromboprotective effect without compromising dose dense carboplatin mediated tumour response. We also discuss the concept of a platinum-focused dose dense “scaffold” that may allow the more feasible integration of single or multiple targeted therapies aimed at reversing platinum resistance specifically, potentially bringing us closer to effective platinum resistance reversal in the clinic.
Patients and methods

Seven consecutive patients with platinum resistant epithelial ovarian cancer (relapse <6 months from last platinum), with grade ≥2 neuropathic symptoms at the time of commencement of dose dense therapy or who developed neuropathy whilst receiving weekly combination carboplatin AUC 3 and paclitaxel 70mg/m² [15], were treated with carboplatin (AUC 3) and paclitaxel (20mg/m²) administered day 1, 8, 15 q4 weekly. Patients were treated at the Department of Medical Oncology, Hammersmith Hospital, London, between 2009 and 2010.

Baseline CT imaging of the chest, abdomen and pelvis was carried out prior to the commencement of therapy and after every 2 cycles (8 weeks). Carboplatin dose was calculated by EDTA clearance [18]. Blood samples for full blood count (FBC), biochemistry, liver function tests (LFTs) and serum CA125 test were taken prior to the commencement of therapy and before each treatment cycle. Patients were reviewed weekly during treatment for safety assessment. All safety evaluations were graded according to the National Cancer Institute Common Toxicity Criteria version 2.0. Consent was obtained from patients prior to the commencement of treatment. Ethics for the retrospective case review was obtained prior to data collection from the Northwick Park Hospital ethical review board.
Results

Patient 1.

Patient 1 was a 63 year old woman diagnosed with a stage 3C, grade 3 papillary serous ovarian carcinoma following suboptimal debulking surgery in 2002. She received 6 cycles of adjuvant carboplatin AUC 6 and paclitaxel 175mg/m² (6/2002 - 11/2002). A complete response was observed on radiologic examination at the completion of therapy. The patient relapsed eight months later (7/2003) and was treated with 6 cycles of conventional schedule of cisplatin 80mg/m² and etoposide 120mg/m² (7/2003 - 1/2004) achieving a partial response. In 2004, she had a second relapse and received 6 cycles of single agent carboplatin AUC 6 to partial response (1/2005 - 6/2005). She was commenced on maintenance tamoxifen 20 mg daily from 7/2005 - 1/2007 was administered for 18 months until relapse when she was treated with platinum sensitive relapse with carboplatin AUC 5 and gemcitabine 1000mg/m². She developed protracted neutropenia after cycle 1 and was subsequently treated with 6 cycles of single agent carboplatin (AUC 6) (1/2007 - 6/2007). She then received palliative radiotherapy to a rectal mass that was completed in July 2007. After a PFI of 5 months she developed disease relapse and commenced dose dense chemotherapy, carboplatin AUC 3 and paclitaxel 75 mg/m² d 1, 8 and 15 q28. Despite having a partial response on CT imaging, paclitaxel was discontinued due to the development of grade 2 peripheral neuropathy and paclitaxel was discontinued. She received 2 weeks of single agent carboplatin (AUC2) but developed dose limiting thrombocytopenia (79 X 10⁹/L) resulting in two weeks dose delay. Low dose paclitaxel, 20 mg/m², was then introduced as a platelet-sparing agent. The carboplatin dose was subsequently increased to AUC 3 (week 7) and then AUC 4 (week 8 and 9). She subsequently developed grade 2 thrombocytopenia requiring a 2 week delay in treatment. Carboplatin dose was reduced to AUC 3 and the patient completed 18 cycles of dose dense therapy. The patient's Serum Ca125 levels decreased from 2332 to 564 U/mL during the course of treatment and her CT confirmed partial response with a significant decrease in the size and number of both subcapsular and intrahepatic metastases (Figure 1). The patient did not experience further thrombocytopenia and her neuropathic symptoms gradually improved whilst on treatment.

Patient 2.

The patient was a 62 year old woman diagnosed with a stage 3C, grade 3 serous ovarian adenocarcinoma diagnosed following optimal debulking surgery in 2007. She received 6 cycles of adjuvant chemotherapy with carboplatin AUC 6 and paclitaxel 175mg/m² (4/2007 - 8/2007). Following a PFI of five months she developed progressive disease, with bilateral hydronephrosis requiring ureteric stents. She was commenced on weekly carboplatin AUC 3 and paclitaxel 75 mg/m² (5/2008 - 10/2008), however her pre-existing grade 2 neuropathy significantly worsened after 5 weekly cycles, and the paclitaxel dose was reduced to 20 mg/m². She completed 18 cycles of therapy with no episodes of thrombocytopenia and without any further deterioration in her neuropathic symptoms. At the end of treatment she had had a partial response both by CT and serum CA125 criteria, from 186 to 12 U/mL, (Figure 2).
**Patient 3.**

**Patient 3** was a 65 year old woman who was diagnosed with stage 3C grade 3 serous ovarian cancer in 2007. She was initially deemed inoperable and received Four cycles of neoadjuvant carboplatin AUC 6 and paclitaxel 175mg/m² administered followed by delayed primary surgery. She then received a further 3 cycles of carboplatin AUC 6 and paclitaxel 175mg/m² (2/2007 - 9/2007). Partial response was noted on the end of treatment CT scan. Serum Ca125 started increasing 4 months following treatment completion with progressive disease confirmed on CT (1/2008) scanning at this time. She was then commenced on weekly carboplatin AUC 3 and paclitaxel 75mg/m² 4 months after last platinum therapy (5/2008 - 10/2008).

She tolerated the first 9 cycles well, however, she subsequently developed clinically significant grade 2 peripheral neuropathy and the dose of paclitaxel was reduced to 20 mg/m². The patient had no delays for haematological toxicity and her peripheral neuropathy resolved on the reduced dose of paclitaxel (Figure 3). She completed 18 cycles of treatment following which CT scan confirmed PR and serum Ca125 decreased from 891 to 78 U/mL.

**Patient 4**

**Patient 4** was a 52 year old woman diagnosed in 2008 following suboptimal debulking surgery for grade 3, stage, 3C serous ovarian cancer. She developed platinum refractory disease on restaging CT scan following 3 cycles of carboplatin AUC 6 and paclitaxel 175mg/m² (6/2008 - 8/2008) suggested platinum refractory disease with progressive intrabdominal disease. She also complained of grade 2 peripheral neuropathy. The patient commenced carboplatin AUC 3 and paclitaxel 20 mg/m² weekly (8/2008 - 1/2009). Paclitaxel was omitted for one week (week 8) for grade 2 arthralgia (solid colour, figure 4) and reintroduced in subsequent cycles. She encountered no delays or dose reductions for toxicity (figure 3). Furthermore, her neuropathic symptoms resolved during the course of her weekly treatment. While an interim assessment suggested anti-tumour activity, at the end of 18 cycles the patient had progressive disease on CT examination.

**Patient 5**

**Patient 5** was a 76 year old woman diagnosed in 2006 with a grade 2, stage 3 serous adenocarcinoma of primary peritoneal origin following an omental biopsy. She was deemed to be of high operative risk because of multiple co-morbidities and received four cycles of neoadjuvant carboplatin AUC 5 followed by delayed primary surgery and 3 further cycles of carboplatin (9/2006 - 4/2007). She developed progressive disease (10/2007) 2 months after completion of therapy and commenced 3-weekly paclitaxel 175mg/m² to stable disease (10/2007 - 2/2008). Treatment was complicated by grade 3 peripheral neuropathy. Three months following completion of therapy she developed progressive disease and commenced on carboplatin AUC 5 in combination with liposomal doxorubicin 40mg/m² completing 6 cycles in November 2008(5/2008 - 11/2008) with a partial response seen on CT. She experienced disease relapse 6 months later and was commenced on weekly carboplatin AUC 3 and paclitaxel 20mg/m² (6/2009 - 10/2009). Therapy was delayed for 2 weeks because of neutropenia (week 3 and 4, although there was no thrombocytopenia) and she was commenced on G-CSF 300µg days 2-5 with each subsequent cycle. Treatment was also delayed for 2 weeks for a tooth extraction (weeks 8 and 9). The last two weeks of treatment were omitted as she developed varicella zoster infection. Her platelet
count and serum CA 125 are shown (figure 45). Her neuropathic symptoms did not worsen during the course of treatment. At the end of 16 cycles the patient had stable disease on CT examination and serum CA 125 reduced from 465 to 89 U/ml.

**Patient 6**

Patient 6 was a 57 year old woman diagnosed with a stage 1A, grade 1 granulosa cell tumour of the ovary following optimal debulking surgery in 2000. She represented three years later with recurrent pelvic and peritoneal disease. She received three cycles of bleomycin, etoposide and cisplatin (3/2004 - 5/2004) however interval CT scan showed no response to therapy, and she was referred for surgery and underwent complete macroscopic debulking. In August 2005 she underwent further debulking surgery for hepatic and splenic metastases and underwent further debulking surgery. In September 2008 she developed hepatic and splenic metastases and underwent further debulking surgery. She commenced 3 weekly carboplatin AUC 6 and paclitaxel 175mg/m² (3/2009 - 5/2009). Interval CT scan after 3 cycles of therapy confirmed progressive disease and she commenced weekly carboplatin AUC3 and paclitaxel 75 mg/m² (5/2009 - 11/2009). Her pre-existing neuropathy significantly worsened (grade 2) after 7 weekly cycles, and the paclitaxel dose was reduced to 20 mg/m². She completed 18 cycles of therapy with no episodes of thrombocytopenia and without any further deterioration in her neuropathic symptoms (Figure 6). At the end of treatment she had had a partial response by CT criteria.

**Patient 7**

Patient 7 was a 57 year old woman diagnosed with a stage 3C serous ovarian cancer following optimal debulking surgery in 2006. She received 6 cycles of adjuvant chemotherapy, with carboplatin AUC 6 and paclitaxel 175mg/m² (10/2006 – 2/2007). Following a treatment free interval of a year later she developed progressive disease and received six cycles of carboplatin AUC 6 and gemcitabine 1000mg/m² (1/2008 – 6/2008). In October 2008 she developed progressive disease and completed six cycles of liposomal doxorubicin in February 2009 (10/2008 - 3/2009). After a platinum free interval of 3 months, she developed progressive disease in May 2009 and commenced treatment with weekly carboplatin AUC 3 and paclitaxel 75 mg/m² June 2009 (6/2009 – 11/2009). However her pre-existing neuropathy significantly worsened (grade 2) after 5 weekly cycles, and the paclitaxel dose was reduced to 20 mg/m² (Figure 7). She completed 16 cycles of therapy with no episodes of thrombocytopenia and without any further deterioration in her neuropathic symptoms. At the end of treatment she had had a partial response on CT and serum CA 125 reduced from 911 to 83 U/ml.

**Discussion**

Several chemotherapeutic agents such as topotecan, gemcitabine, liposomal doxorubicin, paclitaxel and etoposide have been used in the treatment of platinum-resistant disease with unexciting response rates in the range of 6–15% in this platinum-resistant patient group [19-21][16-18]. Data previously published by our group and others suggest that the use of use of extended dose-dense chemotherapy results in response rates of 40 - 60% in this otherwise poor prognosis group [22-24][15, 19, 20]. Extended dose-dense therapy affords the opportunity to effectively and tolerably treat conventionally platinum-resistant patients with platinum again.
This is of importance as platinum resistance ultimately becomes the dominant problem for most patients with ovarian cancer. It is well established that effective administration of single agent carboplatin may be compromised by dose-limiting thrombocytopenia, which may be circumvented by the thromboprotective platelet sparing effect of paclitaxel. However, a limitation in retreating patients with dose dense combination therapy is the development of peripheral neuropathy either because of both following previous taxane therapy or associated with other comorbidities such as diabetes mellitus. In this case series we have shown that the addition of low dose paclitaxel exerts a sufficient platelet sparing thromboprotective effect and does not worsen the clinical symptoms of peripheral neuropathy, and did not impact negatively on the dose intensity or the tumour response to carboplatin.

The major limitation of this report is the small samples size with only seven patients included in this hypothesis generating study. However the results suggest that this approach requires further investigation in the form of a formal randomised phase II feasibility study, and would be strengthened by the inclusion of planned formal nerve conduction studies in such a planned study.

The exact mechanism by which paclitaxel exerts its platelet sparing effect remains unclear. Pertusini and colleagues reported that P-glycoprotein – mediated efflux of paclitaxel, perhaps in association with glutathione S-transferase-mediated detoxification of carboplatin, results in the relative sparing of marrow colony-forming units-megakaryocytes after exposure to carboplatin and paclitaxel. Furthermore, the authors report high levels of circulating serum thrombopoietin in patients receiving combination therapy which was felt to be derived from the marrow stroma. The authors hypothesise therefore that there is relative sparing of megakaryocytes due to reduced drug exposure and these cells are then in turn stimulated by stromal derived thrombopoietin. However, more studies are required to further delineate the exact mechanisms. As the mechanism for this protection is not well understood, there are theoretical concerns that this platelet sparing thromboprotective effect could also protect the tumour. However, several studies including the combined analysis of the ICON4/AGO OVAR 2.2 study showed no survival disadvantage for the combination arm thereby providing some reassurance on this issue. The ICON4 study showed a survival advantage for the combination arm thereby providing some reassurance on this issue.

In the present case series we demonstrate the clinically platelet protective effect of low dose paclitaxel in patients receiving dose dense weekly carboplatin. In all patients the dose of paclitaxel was reduced because of peripheral neuropathy which did not worsen during low dose weekly paclitaxel therapy. We did not feel it was ethical to commence with a low dose of paclitaxel in patients not previously exposed to this drug because of the theoretical problem of developing resistance to paclitaxel. In patient 1, the paclitaxel was initially omitted because of neuropathy and an expected abrupt reduction in platelets was noted despite a concurrent reduction in the carboplatin dose to AUC2. Low dose paclitaxel was then introduced. In order to ascertain the maximal dose of weekly carboplatin that could be administered with low dose paclitaxel, the dose of carboplatin was slowly increased to an AUC 4 when the patient then developed thrombocytopenia suggesting that AUC 3 was the likely
maximal tolerated dose of carboplatin and this dose was subsequently used in the other six patients successfully.

Based on these results, we suggest that with the approach of maximal carboplatin dose and low dose paclitaxel, it may be possible to create an active dose-dense platinum-focussed “scaffold” that can be used to feasibly integrate novel agents that target the reversal of platinum resistance \([27][22]\). With the realisation that delivering carboplatin AUC 3 weekly for 18 cycles is achievable and active in platinum resistant disease, a feasibility study is planned to identify the minimum dose of paclitaxel that is platelet-sparing thromboprotective. This strategy seeks to maximise delivered weekly platinum whilst minimising paclitaxel related toxicities, thereby maximising “space” within the scaffold to absorb potential toxicities of targeted molecular therapies that reverse platinum resistance singly or in combination, since these therapies will bring their own toxicities to the regimen.

Investigators have recently begun to suggest that the response in weekly carboplatin and paclitaxel therapy is principally due to weekly paclitaxel, as judged by the weekly paclitaxel data \([28][23]\). This case series demonstrates that firstly, dose dense carboplatin is feasible in carboplatin focussed scaffolds, and secondly, that from the response profile of these patients, carboplatin given in this way is highly active even with very low dose paclitaxel. A potential therapeutic space is to sequence this approach after patients relapse from weekly paclitaxel; there is a rich seam of targeted therapeutics that may be highly effective in reversing acquired platinum resistance in ovarian cancer in this context that require urgent testing utilising this approach.

Conclusion

In the present case series we have demonstrated that the addition of low dose paclitaxel allows delivery of weekly dose dense carboplatin AUC 3 by maintaining platelet counts without compromising dose dense carboplatin mediated tumour response. In the presIn this paper, we hypothesised that the thromboprotective effect of paclitaxel occurs at doses lower than that required for response. Therefore, patients receiving weekly dose dense therapy who developed neuropathy necessitating the reduction of paclitaxel dose were afforded the opportunity to continue chemotherapy at reduced paclitaxel dose whilst maintaining platinum dose density. We describe here a case series of patients receiving dose dense weekly carboplatin AUC 3 with paclitaxel 20 mg/m\(^2\) day 1, 8, 15 q4 weekly where reductions in paclitaxel dose were required due to clinical indication. We demonstrate that addition of low dose paclitaxel allows delivery of weekly dose dense carboplatin AUC 3 by maintaining the thromboprotective effect without compromising dose dense carboplatin mediated tumour response. We also discuss the concept of a
platinum-focussed dose dense “scaffold” that may allow the more feasible integration of single or multiple targeted therapies aimed at reversing platinum resistance specifically, potentially bringing us closer to effective platinum resistance reversal in the clinic.

We conclude that this regimen is may be feasible and active, and could be formally developed as a “platinum-focussed dose-dense scaffold” into which targeted therapies that reverse platinum resistance can be incorporated, and merits further evaluation.


Competing interests
The authors declare that they have no competing interests

Author contribution
RS: Conception and design of the study, acquisition of data, manuscript preparation and approval of final manuscript
JG: Acquisition of data, data analysis, manuscript preparation and approval of final manuscript
SB: Acquisition of data and approval of final manuscript
HG: Conception and design of the study, acquisition of data, manuscript preparation and approval of final manuscript
All authors read and approved the final manuscript
Figure 1

![Figure 1](image-url)
Figure 2

![Graph representing platelet counts and CA 125 levels over treatment weeks.](image-url)
Figure 3

![Graph showing platelet count and CA 125 levels over weeks on treatment.](image-url)
Figure 4
Figure 5
Figure 6
Figure 7
Additional files provided with this submission:

Additional file 1: figurelegendrv.doc, 22K
http://www.biomedcentral.com/imedia/2062860927555767/supp1.doc
Additional file 2: reviewerscommetns_JG.doc, 78K
http://www.biomedcentral.com/imedia/1650146591555769/supp2.doc